Evidence map›Paper›PMID 33420368›Full record

ArticleOncogene2021

Comparative analysis of the AIB1 interactome in breast cancer reveals MTA2 as a repressive partner which silences E-Cadherin to promote EMT and associates with a pro-metastatic phenotype.

Damir Varešlija, Elspeth Ward, Siobhan P Purcell, Nicola S Cosgrove, Sinéad Cocchiglia, Philip J O'Halloran, Sara Charmsaz, Fiona T Bane, Francesca M Brett, Michael Farrell and 13 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncogene, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. SRC-3, a Steroid Receptor Coactivator: Implication in Cancer.International journal of molecular sciences · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

23 authors at 7 institutions in 3 countries.

Damir VarešlijaEndocrine Oncology Research Group, Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland. damirvareslija@rcsi.ie.ORCID http://orcid.org/0000-0003-1000-0357
Elspeth WardEndocrine Oncology Research Group, Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.ORCID http://orcid.org/0000-0002-7530-2279
Siobhan P PurcellEndocrine Oncology Research Group, Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
Nicola S CosgroveEndocrine Oncology Research Group, Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
Sinéad CocchigliaEndocrine Oncology Research Group, Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.ORCID http://orcid.org/0000-0002-1596-1950
Philip J O'HalloranDepartment of Neurosurgery, National Neurosurgical Center, Beaumont Hospital, Dublin, Ireland.
Sara CharmsazEndocrine Oncology Research Group, Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
Fiona T BaneEndocrine Oncology Research Group, Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
Francesca M BrettDepartment of Neuropathology, National Neurosurgical Center, Beaumont Hospital, Dublin, Ireland.
Michael FarrellDepartment of Neuropathology, National Neurosurgical Center, Beaumont Hospital, Dublin, Ireland.
Jane CryanDepartment of Neuropathology, National Neurosurgical Center, Beaumont Hospital, Dublin, Ireland.
Alan BeausangDepartment of Neuropathology, National Neurosurgical Center, Beaumont Hospital, Dublin, Ireland.
Lance HudsonEndocrine Oncology Research Group, Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
Arran K TurnbulBreast Cancer Now Research Laboratories, Edinburgh, EH4 2XU, UK.
J Michael DixonBreast Cancer Now Research Laboratories, Edinburgh, EH4 2XU, UK.
Arnold D K HillEndocrine Oncology Research Group, Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland.
Nolan PriedigkeitDepartment of Pharmacology and Chemical Biology, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA.
Steffi OesterreichDepartment of Pharmacology and Chemical Biology, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0002-2537-6923
Adrian V LeeDepartment of Pharmacology and Chemical Biology, University of Pittsburgh Cancer Institute, University of Pittsburgh, Pittsburgh, PA, USA.ORCID http://orcid.org/0000-0001-9917-514X
Andrew H SimsApplied Bioinformatics of Cancer Group, University of Edinburgh Cancer Research UK Centre, MRC Institute of Genetics & Molecular Medicine, Western General Hospital, Edinburgh, UK.ORCID http://orcid.org/0000-0001-9082-3665
Aisling M RedmondCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.
Jason S CarrollCancer Research UK Cambridge Institute, University of Cambridge, Li Ka Shing Centre, Robinson Way, Cambridge, CB2 0RE, UK.ORCID http://orcid.org/0000-0003-3643-0080
Leonie S YoungEndocrine Oncology Research Group, Department of Surgery, Royal College of Surgeons in Ireland, Dublin, Ireland. lyoung@rcsi.ie.ORCID http://orcid.org/0000-0002-4904-0367
Royal College of Surgeons in Ireland · IEBeaumont Hospital · IEBreast Cancer Now · GBMagee-Womens Research Institute · USUniversity of Cambridge · GBUPMC Hillman Cancer Center · USWestern General Hospital · GB

Funding

Cancer Research UK 20411
6 · The paper itself

Abstract

Steroid regulated cancer cells use nuclear receptors and associated regulatory proteins to orchestrate transcriptional networks to drive disease progression. In primary breast cancer, the coactivator AIB1 promotes estrogen receptor (ER) transcriptional activity to enhance cell proliferation. The function of the coactivator in ER

Indexed as

Antigens, CDBreast NeoplasmsCadherinsCell ProliferationDisease-Free SurvivalEpithelial-Mesenchymal TransitionEstrogen Receptor alphaFemaleGene Expression Regulation, NeoplasticHistone DeacetylasesHumansMCF-7 CellsNeoplasm MetastasisNuclear Receptor Coactivator 3PhenotypePrognosisAntigens, CDCadherinsCDH1 protein, humanESR1 protein, humanEstrogen Receptor alphaHistone DeacetylasesMTA2 protein, humanNCOA3 protein, humanNuclear Receptor Coactivator 3Repressor ProteinsTamoxifen

Identifiers

PMID33420368
PMCPMC7892341
OpenAlexW3119505580

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.